Fibroscan use to help diagnose acute heart failure in the emergency department
Official title: Evaluation of Fibroscan® Performance in Diagnosing Acute Heart Failure in Patients Presenting to the Emergency Department
Run by Assistance Publique - Hôpitaux de Paris · NCT07449377 · Data updated 2026-11-12
This study tests whether a FibroScan device can quickly help doctors identify acute heart failure in adults who come to the ED with sudden shortness of breath.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris) |
| Status | Recruiting |
| Started | April 2, 2026 |
| Main results expected | May 2027 |
| Study ends | May 2027 |
| Registry record updated | October 27, 2026 |
| Trial ID | NCT07449377 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years and older presenting to the ED with acute dyspnea and no other obvious cause of dyspnea are ideal candidates.
✕Probably not a fit
Patients with chronic liver disease, very low kidney function, pregnancy, or those outside the ED setting may not benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
In this intervention study, researchers assess the use of FibroScan to measure liver stiffness as a potential marker of venous congestion in patients with suspected acute heart failure presenting to the emergency department. The goal is to see if liver stiffness measurements can provide rapid bedside information to aid diagnosis when traditional tests may be delayed or limited. Eligible adults with acute dyspnea and no clear alternative cause can undergo FibroScan as part of their ED assessment. The trial is sponsored by AP-HP with collaboration from Echosens and is conducted at the Paris Pitié-Salpêtrière ED.
Why it matters
Potential benefit: If successful, FibroScan could offer a faster, non-invasive clue to diagnose acute heart failure at the bedside.
How similar studies have gone: Previous research suggests a correlation between liver stiffness and venous congestion in heart failure, supporting a potential role for this approach in acute settings, though evidence in ED-acute presentations is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients ≥18 years 2. ED patients presenting with acute dyspnea and absence of any other obvious cause of dyspnea (for example pneumothorax, acute pneumonia, acute coronary syndrome, Covid) … 3. Social security affiliation (except AME) 4. Informed consent signed Exclusion Criteria: 1. Known chronic liver disease, defined by a Prothrombic time of \< 50%, or any former diagnosis of liver fibrosis. 2. No skin wounds in the abdominal area on which the Fibroscan® will be used 3. History of liver transplantation 4. eGFR \<30 mL/min 5. Patient under legal protection measure (tutorship or curatorship) and patient deprived of freedom 6. Pregnancy and breastfeeding 7. Participation in another interventional trial
Where it's running
-
Name: Emergency Department Hospital Pitié-Salpêtrière, APHP
Paris, France Recruiting
Study contacts
- Principal investigator: Amélie VROMANT, Medical Doctor — Assistance Publique - Hôpitaux de Paris
- Study coordinator: Amélie VROMANT, Medical Doctor
- Email: amelie.vromant@aphp.fr
- Phone: +33617253512
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comprehensive clinical rule to diagnose acute heart failure in the emergency department
A prospective study tests a combined clinical rule using patient data, a point-of-care NT-proBNP test, an 8-point lung ultrasound, and bedside echo to quickly diagnose acute heart failure in adults with new or worsening symptoms.
-
Disrupted congestion in acute heart failure: can ultrasound at discharge predict readmission and death
This study tests whether ultrasound checks of congestion at discharge can predict which patients with acute heart failure are more likely to be readmitted or die within 90 days.
-
Pre-discharge Flu Vaccine for patients with acute heart problems
This trial tests whether giving an influenza vaccine within 24 hours before hospital discharge helps patients who were treated for acute heart issues stay healthier this season.
-
Acute Heart Failure: How a Quantitative ECG Helps Clinicians
This study tests whether quantitative ECG (QCG) measurements can reveal useful patterns in adults hospitalized with acute heart failure.
-
Urinary Sodium and Chloride Changes and Fluid Overload in Acute Heart Failure
This study tests whether tracking urinary sodium and chloride during hospitalization can reflect congestion removal and predict short-term outcomes in adults with acute heart failure treated with IV diuretics.
-
Training medical residents to use the Venous Excess Ultrasound (VExUS) score for bedside volume assessment
This project tests whether in-person or remote training better teaches medical residents to use the VExUS ultrasound score for bedside volume checks in patients with acute heart failure.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.